Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35121621.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Utilizing advanced RNA-sequencing techniques and rigorous bioinformatics analysis, this study identified gene signatures predicting responsiveness to pembrolizumab monotherapy. T-cell-inflamed gene expression profile was predictive for better treatment response, while angiogenesis, monocytic myeloid-derived suppressor cell, and stroma/epithelial-mesenchymal transition/TGFβ gene signatures were associated with lower treatment response. See related article by Cristescu et al., p. 1680.
Medical subject headings
- Immune Checkpoint Inhibitors
- Myeloid-Derived Suppressor Cells